Visits | ARV | Medical visits | ||
---|---|---|---|---|
Poor CD4 response ¥ | ||||
 | Crude RR (95% CI) | Adjusted RR £ (95% CI) | Crude RR (95% CI) | Adjusted RR £ (95% CI) |
Missed visit status | Â | Â | Â | Â |
   1 vs. 0 | 1.02 (0.88-1.19) | 1.02 (0.87-1.18) | 1.15 (1.00-1.33) | 1.12 (0.98-1.29) |
   2 vs. 0 | 1.36 (0.99-1.85) | 1.33 (0.98-1.80) | 1.22 (0.90-1.65) | 1.19 (0.89-1.61) |
   ≥ 3 vs. 0 | 1.24 (0.37-4.14) | 1.62 (0.49-5.34) | 2.11 (1.91-3.74) | 2.27 (1.35-3.83) |
Age at initiation | Â | Â | Â | Â |
   18-24.9 vs. ≥50 | 0.46 (0.31-0.69) | 0.52 (0.35-0.78) | 0.46 (0.31-0.69) | 0.52 (0.34-0.77) |
   25-29.9 vs. ≥50 | 0.56 (0.43-0.72) | 0.62 (0.48-0.79) | 0.56 (0.43-0.72) | 0.61 (0.48-0.79) |
   30-39.9 vs. ≥50 | 0.69 (0.57-0.83) | 0.73 (0.61-0.88) | 0.69 (0.57-0.83) | 0.73 (0.60-0.88) |
   40-49.9 vs. ≥50 | 0.82 (0.67-1.01) | 0.84 (0.69-1.02) | 0.82 (0.67-1.01) | 0.83 (0.68-1.02) |
Baseline CD4 count (cells/mm3) | Â | Â | Â | Â |
   51-100 vs. 100-200 | 0.76 (0.65-0.89) | 0.76 (0.65-0.89) | 0.76 (0.65-0.89) | 0.77 (0.64-0.88) |
   0-50 vs. 100-200 | 0.68 (0.59-0.78) | 0.68 (0.59-0.79) | 0.68 (0.59-0.78) | 0.68 (0.60-0.79) |
Baseline NRTI | Â | Â | Â | Â |
   AZT vs. d4T | 1.41 (0.80-2.49) | 1.42 (0.81-2.50) | 1.41 (0.80-2.49) | 1.46 (0.83-2.57) |
Baseline NNRTI | Â | Â | Â | Â |
   NVP vs. EFV | 0.84 (0.66-1.08) | 0.92 (0.72-1.18) | 0.84 (0.66-1.08) | 0.93 (0.73-1.19) |
Sex | Â | Â | Â | Â |
   Male vs. female | 1.40 (1.24-1.58) | 1.33 (1.18-1.51) | 1.40 (1.24-1.58) | 1.32 (1.17-1.50) |
Failure to suppress viral load € | ||||
---|---|---|---|---|
Missed visit status | Â | Â | Â | Â |
   1 vs. 0 | 1.15 (0.89-1.50) | 1.19 (0.89-1.51) | 1.24 (0.97-1.58) | 1.23 (0.96-1.57) |
   2 vs. 0 | 2.09 (1.33-3.29) | 1.93 (1.12-3.32) | 2.18 (1.47-3.24) | 2.28 (1.54-3.36) |
   ≥ 3 vs. 0 | 4.35 (1.71-11.0) | 5.75 (2.97-11.1) | 3.19 (1.34-7.58) | 3.00 (1.28-7.06) |
Age at initiation | Â | Â | Â | Â |
   18-24.9 vs. ≥50 | 1.64 (0.98-2.74) | 1.55 (0.90-2.73) | 1.64 (0.98-2.74) | 1.41 (0.83-2.38) |
   25-29.9 vs. ≥50 | 1.13 (0.73-1.77) | 1.01 (0.62-1.64) | 1.13 (0.73-1.77) | 0.96 (0.61-1.52) |
   30-39.9 vs. ≥50 | 0.98 (0.66-1.46) | 0.99 (0.65-1.50) | 0.98 (0.66-1.46) | 0.92 (0.62-1.36) |
   40-49.9 vs. ≥50 | 0.92 (0.60-1.40) | 0.93 (0.58-1.47) | 0.92 (0.60-1.40) | 0.85 (0.56-1.31) |
Baseline CD4 count (cells/mm3) | Â | Â | Â | Â |
   51-100 vs. 100-200 | 0.97 (0.74-1.20) | 0.96 (0.70-1.30) | 0.97 (0.74-1.20) | 0.99 (0.75-1.30) |
   0-50 vs. 100-200 | 0.93 (0.74-1.29) | 0.94 (0.72-1.24) | 0.93 (0.74-1.29) | 0.92 (0.72-1.19) |
Baseline NRTI | Â | Â | Â | Â |
   AZT vs. d4T | 1.41 (0.80-2.49) | 1.69 (0.93-3.05) | 1.41 (0.80-2.49) | 1.60 (0.93-2.75) |
Baseline NNRTI | Â | Â | Â | Â |
   NVP vs. EFV | 0.79 (0.56-1.12) | 1.12 (0.75-1.67) | 0.79 (0.56-1.12) | 1.22 (0.86-1.73) |
Sex | Â | Â | Â | Â |
   Male vs. female | 0.81 (0.65-1.01) | 0.80 (0.60-1.04) | 0.81 (0.65-1.01) | 0.85 (0.67-1.07) |